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Abstract
The Chikungunya virus infection zones have now quickly spread from Africa to parts of Asia, North America and Europe.
Originally thought to trigger a disease of only mild symptoms, recently Chikungunya virus caused large-scale fatalities and
widespread economic loss that was linked to recent virus genetic mutation and evolution. Due to the paucity of information
on Chikungunya immunological progression, we investigated the serum levels of 13 cytokines/chemokines during the acute
phase of Chikungunya disease and 6- and 12-month post-infection follow-up from patients of the Italian outbreak. We
found that CXCL9/MIG, CCL2/MCP-1, IL-6 and CXCL10/IP-10 were significantly raised in the acute phase compared to follow-
up samples. Furthermore, IL-1b, TNF-a, Il-12, IL-10, IFN-c and IL-5 had low initial acute phase levels that significantly
increased at later time points. Analysis of symptom severity showed association with CXCL9/MIG, CXCL10/IP-10 and IgG
levels. These data give insight into Chikungunya disease establishment and subsequent convalescence, which is imperative
to the treatment and containment of this quickly evolving and frequently re-emerging disease.
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Introduction
The Chikungunya virus (CHIKV), an arthropod-borne virus
(arbovirus), is a single-stranded positive-sense RNA virus with
three genotypes. The virus is of the Alphavirus genus in the
Togaviridae family [1,2]. CHIKV has been shown to infect and be
transmitted by Ae. aegyptii and Ae. albopictus mosquitoes. It was
identified in East Africa in the early 1950s and since then has
caused epidemics in continental Africa, the Indian Ocean region,
and countries of Southeast Asia such as India, where since 2006
suspected cases have been estimated to be 1.39 million, and
Singapore [3–6]. The only reported outbreak outside these areas
was in Italy in the Emilia Romagna region in 2007. Small non-
epidemic imported cases have been reported in other regions such
as North America, France and Japan, which were caused by
travelers returning from affected areas [7–9].
The epidemic occurring on La Reunion Island in the Indian
Ocean remains the most devastating of all CHIKV outbreaks
where over one-third of the population was affected [10]. During
this outbreak, the CHIKV acquired a genetic mutation allowing
the new vector Ae. albopictus mosquito to carry the virus where
previously CHIKV only circulated in Ae. aegyptii mosquitoes
[10,11]. The Ae. albopictus differs in susceptibility to various
genetically different isolates of the virus compared to the Ae. aegyptii
[12]. CHIKV is now of global health concern since expansion of
mosquito vectors has created potential for the Chikungunya virus
to spread to temperate areas as Ae. albopitcus inhabits regions in
North America and Europe [2,13].
CHIKV infection is clinically characterized by the sudden
appearance of high fever, rash, headache, nausea, vomiting,
myalgia and arthalgia or severe joint pain. Severe joint pain is the
defining symptom of CHIKV disease [11]. The word Chikungunya
originated from the Tanzanian and Mozambique region of Africa
meaning that which bends up. A bent posture is often taken by those
in severe joint pain after being infected with CHIKV. CHIKV
symptoms start 4 to 7 days after exposure and most resolve within
the acute phase of the disease. Although the acute phase lasts
approximately 2 weeks, joint pain can persist for months or years
following initial infection [1,14,15]. Minimal research has been
done investigating the immune response following CHIKV
infection. Currently, there is no CHIKV specific therapeutic
available.
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surrounding the city of Ravenna during August to October 2007
and also involved the major Italian city of Bologna [15,16]. A
recorded 254 people were identified to be infected through the Ae.
albopictus mosquito which has inhabited the Emilia Romagna
region since 1990 [14,17,18]. The virus brought to the Emilia
Romagna region by a traveler returning from a CHIKV affected
country was of the Central/East African genotype and matched
most closely (100% amino acid identity) with the IND-06 virus
isolated from the Reunion Island outbreak [14,17]. The amino
acid identity confirmed that this virus included a substitution
mutation in the E1 envelope protein (E1-A226V) [19] which is
important for viral entry into host cells. This mutation was
acquired during the 2005-2006 Indian Ocean CHIKV outbreak
and increased the virus’s infectivity to the Ae. albopictus mosquito
[20].
Cytokines are important immune mediators that conduct
immune responses. Recently, cytokine profiles have been investi-
gated in CHIKV infected humans by two groups [21,22]. Ng and
colleagues established cytokine profiles from 10 CHIKV patients
that were infected during the Singapore 2007 CHIKV outbreak
[22]. Although this study reported that IL-1b, IL-6 and RANTES
were correlated with severe acute phase CHIKV disease, cytokine
profiles were not determined for the progression and convales-
cence of the disease. Here we investigated cytokine profiles during
the acute phase and 6- and 12-month follow-up of CHIKV
infected patients of the Italian 2007 outbreak. Since CHIKV
disease can have severe acute phase symptoms and be followed by
persistent symptoms in the convalescence phase it was important
to investigate the immune response responsible for these maladies.
Furthermore, the Italian CHIKV included the A226V mutation
and the Singapore virus did not. Furthermore, we analysed the
relationship between cytokine levels and patient severity, and IgG
levels linking high CXCL9, CXCL10 and IgG levels with disease
severity. Therefore, the results presented here are virus specific
and reflect previously unreported cytokine profiles which may be
important for the development of future therapeutics for CHIKV
outbreaks.
Materials and Methods
Ethics statement
Patients all gave written consent to the participation in scientific
studies. Permission to perform scientific studies was given by
Comitato Etico di Area Vasta Romagna Et IRSTof the Servizio
Sanitario Regionale Emilia-Romagna, Italy.
Objectives
Since the immune response during CHIKV disease has not
been extensively investigated, our objectives were to create a clear
clinical picture of CHIKV disease at the acute phase and during
convalescence at 6- and 12-month follow-up by cytokine pro-
filing. To achieve this objective, we investigated the cytokine
profiles from patients at the acute phase and at 6- and 12-month
follow-up.
Participants
Included patients were from the region of Emilia-Romagna in
north-east Italy suspected to be infected with CHIKV since they
showed symptoms such as myalgia, severe back and joint pain,
headache, and skin rash. Collaboration with the regional
microbiology reference laboratory of Bologna University and the
Department of Infectious and Parasitic Diseases of the National
Institute of Health in Rome was initiated and identified the
patients as having CHIKV. The clinical criteria was described as
acute onset of fever (.38.5uC) and severe arthralgia not explained
by other medical conditions. CHIKV infection was confirmed by
one or more of the acute phase tests: virus isolation, reverse
transcriptase-PCR (RT-PCR) positive for CHIKV nsp1 gene,
seroconversion to virus-specific serum antibodies collected at least
1 to 3 weeks apart, or presence of virus-specific IgM antibodies in
a single serum sample collected [15]. Acute CHIKV patient
samples were determined to be in the viral stage if the sample was
PCR positive for CHIKV (7 patients), in the IgM antibody
initiation stage if the sample was PCR negative, IgM positive, IgG
negative (6 patients) or in the seroconversion stage (22 patients) if
the sample was PCR negative, IgM positive and IgG positive. The
samples were considered to be high IgG if the IgG level was
greater than 6400 (6 months) (31 patients high out of 50) or greater
than 3200 (12 months) (20 patients out of 50). IgG levels below or
equal to these thresholds were considered low IgG. CHIKV
patients were considered to be non-symptomatic (15 patients out
of 50 at the 6-month follow-up; 34 patients out of 50 at the 12
month follow-up), have mild symptoms (21 patients out of 50 a the
6 month follow-up; 14 patients out of 50 at the 12 month follow-
up), or have severe symptoms (14 patients out of 50 at the 6 month
follow-up; 2 patients out of 50 at the 12 month follow-up) based on
their responses to a questionnaire at the time of sampling which
was based on: articular pain, muscle pain, mono-arthritis, oligo-
arthritis, symmetric polyarthritis, asymmetric polyarthritis, teno-
synovitis, arthralgia and fibromyalgia. Control samples were
collected from 10 healthy volunteers screened for symptoms of
viral infection.
Patient sample collection
Blood samples were collected from consenting CHIKV positive
patients at the time of diagnosis. Viral infection was determined as
described above. Two follow-up samples were then collected from
each patient at the 6-month evaluation and the 12-month
Author Summary
Chikungunya virus (CHIKV) is transmitted by mosquitoes
and causes a human disease clinically characterized by
sudden appearance of high fever, rash, headache, nausea,
and severe joint pain (the defining symptom). Chikungu-
nya was identified in Africa and the word Chikungunya
means that which bends up, describing the bent posture of
CHIKV patients while in severe pain. CHIKV, a current
problem in Africa, Indian Ocean region, and Southeast
Asia, is now spreading to temperate regions of North
America, France and Italy. Presently, the immune response
for CHIKV infection remains largely uninvestigated and no
treatment is available. We investigated cytokine profiles at
diagnosis and follow-up of CHIKV infected patients during
the Italian 2007 outbreak and associated cytokine levels
with antibody level and symptom severity. Cytokines,
important immune mediators, are often drug targets. Since
CHIKV symptoms can persist for months or years following
infection it is important to investigate possible drug
targets to alleviate discomfort. We found cytokine profiles
that describe the initial infection and recovery phase. We
determined the cytokines CXCL9/MIG and CXCL10/IP-10 as
well as antibody levels were associated with symptom
severity. These results reflect previously unreported
cytokine profiles which may be important for the
development of future therapeutics for CHIKV outbreaks.
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frozen at 280uC until serum analysis.
CBA
Serum samples were analyzed for cytokine levels using BD
TM
Cytometric Bead Array (CBA) Human Chemokine Kit, Human
Inflammatory Cytokine Kit, and Human Th1/Th2 Cytokine Kit
(BD Biosciences) according to the manufacturer’s instructions for a
total of 13 cytokines. Capture Beads were added to the serum
sample followed by the PE detection reagent. The samples were
then incubated for 3 hours at room temperature and washed with
the assay Wash Buffer and resuspended again in Wash Buffer for
analysis on the Flow Cytometer. CBAs were then run on a BD
FACSCalibur Flow Cytometer.
Statistical analysis
CBA data was analysed using SPSS statistical software. Box-
whisker plots were created from the CBA FACS raw data. Six-
month and 12-month samples were compared to the acute
samples using the non-parametric two-tailed Wilcoxon signed-
rank test for related samples to determine statistical significance.
Each acute phase, 6-month and 12-month cytokine sample sets
were statistically compared to healthy control CBA data using the
non-parametric two-tailed Mann Whitney Test for unrelated
samples.
Results
CHIKV resolution is associated with differential cytokine
programs of increasing and decreasing trends
CHIKV causes a disease of crippling joint pain that has affected
most of Asia and has demonstrated the capability to spread to non-
tropical areas such as Europe and parts of North America [1].
Cytokines are inflammatory mediators and their balance is often
associated with inflammatory disease [23]. Previously, the cytokine
profiles of acute phase CHIKV patients have been examined [22].
Here we profiled cytokine levels in acute phase and 6- and 12-
month follow-up CHIKV patient serum samples to determine a
cytokine signature that may correlate with acute symptoms,
following persistent joint pain and/or disease resolution. Blood
samples were collected from 50 patients suffering from CHIKV
infections during the 2007 Italian outbreak. Serum separated from
whole blood was analyzed by cytokine bead analysis (CBA) for 13
cytokines with the intention of determining a cytokine profile
during CHIKV acute phase and disease convalescence. Three
cytokine profiles emerged from our data: decreasing, increasing
and no-trend.
The first trend showed cytokine levels significantly higher in the
acute samples compared to the follow-up time points revealing a
decreasing pattern as patients left the acute phase. CXCL9/MIG
(CXCL9), IL-6, CCL2/MCP-1(CXCL2) and CXCL10/IP-10
(CXCL10) cytokines had significantly decreased at both 6-month
and 12-month follow-ups (Figure 1). Interestingly, some patients
had extremely high levels in the acute phase; CXCL9 and
CXCL10 levels decreased 1000 fold to 10,000 fold during
convalescence. Furthermore, the decreasing trends for IL-6,
CXCL9, and CXCL10 reached similar levels as those of the
community control levels (shown by dotted line). CCL2 levels
decreased significantly lower than the control levels by 12 months.
Taken together, this data demonstrated that CXCL9, IL-6, CCL2
and CXCL10 were initially increased with acute CHIKV infection
and decreased over time.
The second cytokine trend that emerged described cytokines
that significantly increased following the acute phase. Cytokine
profiles that were markedly lower in the acute phase and
subsequently increased included IL-1b, TNF-a, IL-12, IL-5, IL-
10 and IFN-c (Figure 2). The cytokine increase was more gradual
than the previous decreasing trend, where fold changes were
generally closer to 2. Both the 6- and 12-month follow-up were
statistically increased compared to acute values for IL-5 levels. IL-
1b, TNF-a, IL-12, IL-10 and IFN-c had significantly increased by
12 months. Even though the average for these cytokines had also
risen by 6 months it was not significant. Furthermore, the
increasing trends for TNF-a, IL-5, and IL-10 reached similar
levels to the community control levels (shown by dotted line) and
IFN-c reached significantly higher than controls at 12 months.
Interestingly, although IL-1b and IL-12 increased through the
observed time, these cytokines stayed significantly lower than those
of the controls. This data showed that cytokines IL-1b, TNF-a, IL-
12, IL-5, IL-10 and IFN-c increased in the convalescence phase of
CHIKV infection.
No significant change was seen for IL-2, IL-4, and IL-8 from the
acute phase to the 12-month follow-up (Figure 3). Interestingly,
IL-2 reached similar levels to those of the controls where IL-8 and
IL-4 remained significantly raised and lowered, respectively.
CXCL10, CXCL9, IL-6 and IL-10 are possible biomarkers of
virus, IgM and IgG levels in CHIKV patient serum
Previously, we have shown that the acute phase of West Nile
Virus (WNV) can be described in 3 stages [24]. Since the samples
from the CHIKV patients were taken at various stages of the acute
phase, we went on to determine if there were cytokines marking
the viral (V), IgM antibody initiation (AI) or seroconversion (SC)
stage. Acute CHIKV patient samples were determined to be PCR
positive for CHIKV (viral stage), IgM positive, IgG negative (IgM
antibody initiation stage) or IgM positive, IgG postive (serocon-
version stage). Samples were put into Viral stage (V), Antibody
Initiation stage (AI) or Seroconversion stage (SC) according to the
presence of CHIKV, IgM and IgG antibodies. Cytokine Bead
Array analysis of the serum samples showed a significant decrease
in CXCL10 and IL-10 from the viral stage to the seroconversion
stage of the acute phase (Figure 4). The median of CXCL10 in the
viral stage was approximately 7000 pg/ml and dropped to less
than 1000 pg/ml after seroconversion. Interestingly, the IL-10
median decreased by 3 fold from the viral stage to the
seroconversion stage.
Next we sought to determine if the high levels of IgG in the
follow-up phases were also significantly associated with cytokine
levels compared to the cytokine levels of patients with low levels
of IgG. The patients were put into an IgG high group (H) or an
IgG low group (L) and the levels of each cytokine were
statistically compared for each group using the Mann-Whitney
U Test. In the 6-month follow-up phase CXCL9, CXCL10 and
Il-6 were found to be statistically different between the high IgG
group and the low IgG group (Figure 5A). High levels of all 3
cytokines were associated with high levels of IgG antibodies. IL-
10 is also shown for comparison since it was statistically
significant during the acute phase breakdown and the 12-month
follow-up. Interestingly, in the 12-month follow-up phase,
CXCL9 was found to be statistically higher in the IgG high
group where IL-10 was significantly lower in the high IgG group
(Figure 5B). CXCL10 is shown for comparison at 12 months
although it was not significantly different between the IgG high
and IgG low groups. In summary, the results suggested that
CXCL9, CXCL10 and Il-6 were associated with IgG levels in the
6-month follow-up phase and CXCL9 and IL-10 in the 12-
month follow-up phase.
Inflammatory Cytokines Resolve Chikungunya Disease
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CHIKV disease severity
IL-1b, IL-6 and RANTES were found to be associated with
symptom severity of the Singapore 2007 CHIKV outbreak [22].
After determining the cytokine profiles of our Italian 2007
CHIKV patients during their disease resolution, we next sought
to determine the association between symptom severity and
cytokine levels. Patients were determined to be non-symptomatic
(N), to have mild symptoms (M) or to have severe symptoms (S)
depending on their responses to a questionnaire. The cytokine
levels were then grouped by symptom level and a Mann-Whitney
U test was used to determine significance among the severity
groups for each cytokine. CXCL10 and CXCL9 were found to be
significantly increased in the patients with mild and severe
symptoms at 6 months following initial infection compared to
the patients reporting no symptoms (Figure 6A). A 2 fold
difference was seen between the medians of the non-symptomatic
and severe patients for CXCL10 and a 5 fold difference for
CXCL9. No statistical difference was seen for any of the 13
cytokines profiled for the 12-month follow-up. CXCL10 and
CXCL9 at 12 months are shown for comparison (Figure 6B).
Moreover, we analyzed the IgG levels at the 6-month follow-up in
patients with no symptoms, mild symptoms, and severe symptoms.
The results showed IgG levels were statistically increased with
Figure 1. Acute phase CHIKV disease was associated with high levels of IL-6, CXCL9, CCL2, CXCL10. Cytokine Bead Array analysis of
CHIKV patient serum samples showed high levels of IL-6, CXCL9, CCL2 and CXCL-10 are associated with acute disease phase and decreased with
patient convalescence. Six-month and one-year cytokine levels were analysed for statistical significance using the Wilcoxon test for Significanceb y
comparing with acute levels. All samples were also analyzed for significance against healthy controls by the Mann-Whitney U test. The cross symbol
indicates a p-value less than 0.05 for 6- and 12-month groups compared to acute values and star symbol indicates a p-value less than 0.05 for acute,
6- and 12-month groups compared to control values. The dotted line indicates the median of healthy control cytokine levels. Acute (A), 6-month
follow-up (6), and 12-month follow-up (12).
doi:10.1371/journal.pntd.0001279.g001
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www.plosntds.org 4 August 2011 | Volume 5 | Issue 8 | e1279Figure 2. CHIKV patient convalescence was associated with increasing levels of TNF-a, IL-5, IL-1b, IL-12, IFN-c and IL-10. Cytokine
Bead Array analysis of CHIKV patient serum samples showed that following the acute phase of CHIKV disease patients had increasing levels of TNF-a,
IL-5, IL-1b, IL-12, IFN-c and IL-10. Six-month and one-year cytokine levels were analysed for statistical significance using the Wilcoxon test for
Inflammatory Cytokines Resolve Chikungunya Disease
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suggested CXCL10, CXCL9 and IgG to be possible markers of
CHIKV severity during early phases of disease resolution.
Discussion
CHIKV disease is a self-limiting disease caused by an alphavirus
of the Togaviridae family. Although historically the virus only caused
a disease of mild symptoms, a recent outbreak on La Reunion
Island caused significant mortality due to genetic alterations
[1,20,22,25,26]. Here we have investigated the immune response
of an Italian population infected with the Indian Ocean genotype
of CHIKV and have generated a cytokine signature for the initial
infection to convalescence phase of CHIKV disease, the signature
of viral and antibody production phases, and identified cytokines
raised in patients with severe symptoms. We found that initial
Figure 3. IL-2, IL-8 and IL-4 were not associated with acute or convalescence phase of CHIKV disease. Cytokine Bead Array analysis of
CHIKV patient serum samples showed that IL-2, IL-8 and IL-4 were not associated with acute phase or convalescence of CHIKV disease in patients. Six-
month and one-year cytokine levels were analysed for statistical significance using the Wilcoxon test for Significance by comparing with acute phase
values. Samples were analyzed for significance against healthy controls by the Mann-Whitney U test. The star symbol indicates a p-value (Mann-
Whitney U test) less than 0.05 acute, 6- and 12-month groups compared to control values. The dotted line indicates the median of healthy control
cytokine levels. Acute (A), 6-month follow-up (6), and 12-month follow-up (12).
doi:10.1371/journal.pntd.0001279.g003
Significance by comparing with acute phase values. As well, samples were analyzed for significance against healthy controls by the Mann-Whitney U
test. The cross symbol indicates a p-value (Wilcoxon test) less than 0.05 for 6- and 12-month groups compared to acute values and star symbol
indicates a p-value (Mann-Whitney U test) less than 0.05 acute, 6- and 12-month groups compared to control values. The dotted line indicates the
median of healthy control cytokine levels. Acute (A), 6-month follow-up (6), and 12-month follow-up (12).
doi:10.1371/journal.pntd.0001279.g002
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set of decreasing and increasing cytokines. Furthermore, we have
shown that CXCL10 and IL-10 levels were associated with the
viral stage of the acute phase and CXCL10 and CXCL9 with high
IgG levels of the 6-month follow-up. As well, CXCL10 and
CXCL9 were markers of symptom severity. Importantly, these
identified signatures depict the immunological programs and may
be key to the development of therapeutics for the frequently re-
emerging CHIKV disease.
Our analysis has indentified 2 cytokine profiles that followed
disease onset and continued with disease progression/convales-
cence. We found CXCL9, CXCL10, CCL2 and IL-6 levels were
high in the acute phase and decreased as patients convalesced.
Conversely, the trend for TNF-a, IL-1b, IL-2, IL-5 and IL-12
were low initially and increased as patients began to recover from
acute illness. High levels of CXCL9, CXCL10, CCL2, and IL-6 in
the acute phase possibly indicated an inflammatory program
initiating adaptive T-cell immunity [27]. CXCL9 and CXCL10
are both chemokines induced by IFN-c and are part of the
chemokine program that regulates the migration of monocytes/
macrophages, memory T cells and NK cells and are associated
with the polarization of T cells [27]. IL-6, a pleiotropic cytokine,
has a destructive role in rheumatoid arthritis (RA), contributing to
joint inflammation as well as joint pain [28,29]. The increased IL-
6 levels in the acute phase of our study may be the initiating factor
of the severe joint pain symptoms reported in CHIKV patients
which mimics RA. Furthermore, IL-6 is important during acute
phases of the disease by acting as an important immune mediator
of fever activating muscle metabolism to increase core body
temperature [28]. Since fever is a common symptom of acute
CHIKV disease, it is highly probable that the high IL-6 levels were
contributing to the acute fever and the IL-6 decreasing trend
followed patient core body temperature as it returned to resting
temperature in the follow-up.
A second host immune response profile was characterized by
TNF-a, IL-1b, Il-10, Il-12, IFN-c and IL-5, which increased from
Figure 4. The stages of CHIKV Acute phase were marked by changes in CXCL10 and IL-10. Acute CHIKV patients were categorized into
Viral stage (V), Antibody Initiation stage (AI) or Seroconversion stage (SC) according to the presence of CHIKV, IgM and IgG antibodies. Cytokine Bead
Array analysis of the serum samples showed a significant decrease in CXCL10 and IL-10 from the Viral stage to the Seroconversion stage of the Acute
phase. A Mann-Whitney U test was used to determine significance among the phases. The star symbol indicates a p-value less than 0.05 compared to
the Viral phase.
doi:10.1371/journal.pntd.0001279.g004
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10 respectively. IgG levels in 6- and 12-month patient serum samples were determined by ELISA. The samples were then grouped by IgG level; a
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1b, which are known to co-induce the other’s expression, are both
involved in chronic inflammatory diseases such as RA, chronic
hepatitis B and C infection [23,29,30]. Importantly, TNF-a and
IL-1b are main contributors to joint pain, which is the major
symptom of RA. An internal balance of TNF-a or IL-1b levels is
imperative as mis-regulation of either has been shown to be a
major proponent of chronic diseases (RA). Our data indicated that
these cytokines increased significantly during patient convales-
cence above those of the control group, but were not statistically
changed in patients reporting mild or severe symptoms. These
data may imply that the increased levels of TNF-a and IL-1b in
the convalescence phase were not a major contributor of chronic
damage causing persistent severe joint pain symptoms during the
Italian outbreak even though these cytokines have previously been
found to play a destructive role in chronic inflammatory diseases.
Furthermore, TNF-a immunomodulators have previously been
used as a common treatment for RA and IL-1b immunomodu-
lators are effective with other chronic diseases such as systemic-
onset juvenile idiopathic arthritis and in adult onset Still’s diseases
[29,31]. Taken together, these findings suggest TNF-a and IL-1b
therapies would not be effective controlling the prolonged
symptoms of CHIKV disease since the raised levels during
convalescence were not associated with patient severity.
Previously, cytokine profiles have been analyzed from patients
during an Asian outbreak of CHIKV [22]. Ng and colleagues,
investigated 30 cytokines and growth factors from 10 acute phase
CHIKV patients, determined that the levels of 8 cytokines, 2
chemokines and 3 growth factors were significantly raised in
patients compared to those of the control group. In accordance
with their data, IL-6, CXCL9 and CXCL10 were also increased in
the acute phase of our patients as compared to control. Since the
results from the previous study did not follow the patients during
convalescence, our study added significant insight to the
progression of CHIKV disease. We found that these three
cytokine levels decreased as the patients convalesced as discussed
above. Conversely, we found CCL2 also to be increased in the
acute phase compared to that of the control group, which was
unchanged in the Ng study. Furthermore, Ng et al. found IL-5 and
IL-10 were significantly increased in the acute phase where our
data indicated that IL-5 and IL-10 were initially low and below
control levels and increased following the acute phase. These
discrepancies can possibly be explained by the patient populations:
the Ng study patients and our patients were from significantly
varied genetic backgrounds (Asian and European, respectively).
Therefore, differences in immune response may reflect variations
in immunological genetic programs. As well, the virus that caused
the two outbreaks also differed genetically. Even though the virus
that caused the Singapore outbreak was the same genotype as the
Italian virus, the virus that infected the Italian patients had the
A226V mutation in the E1 gene which was acquired on La
Reunion Island [19]. Although the impact of this mutation has
been shown to increase vector infectivity [20], the mutation has
not been investigated on the human or mammalian immune
response.
Previously, we have identified 3 stages of the acute phase of
WNV; a viral stage, antibody initiation stage, and seroconversion
stage [24]. As the viral load decreased in the WNV patients, IgM
antibody levels were initiated and followed by IgM conversion to
IgG, thereby marking the 3 stages of the acute phase. From this
work we were able to identify the stages of the CHIKV patients
and compare their respective serum cytokine levels. We found
CXCL10 and IL-10 levels decreased as patients progressed
through the viral stage to seroconversion. Since CXCL10 is often
correlated with viral load, this observation was not surprising [32].
High IL-10 levels in the viral stage may act in an effort to control
the IFN-c program [33] shown by high CXCL10 levels.
Furthermore, plasma levels of CCL2, IL-6 as well as CXCL10
have all been correlated with viral loads in virus infected
individuals [24,34,35]. It is possible that the decrease of CCL2
and IL-6 we observed subsequent to the acute phase [14]
correlated with viral clearance, although not with antibody levels.
Analysis of the cytokine/antibody response was carried on to the
6- and 12-month follow-up where we grouped the patients on their
IgG levels. CXCL9, CXCL10 and IL-6 were raised in the patients
with increased IgG levels at 6 months and CXCL9 at the 12-
month follow-up. These proinflammatory cytokine associations
with high IgG levels may represent the persistence of an active
immune system.
CXCL9 and CXCL10 as well as high IgG levels were found to
be biomarkers of severe CHIKV symptoms. Previously, CXCL10
has been associated with severe viral disease supporting a role for
CXCL10 in severe CHIKV disease [34–37]. These studies did not
find an association with CXCL9 and severity as seen in our
CHIKV patients. Our findings suggest high CXCL10 and
CXCL9 associated with severity to be a unique signature of
CHIKV. Interestingly, not only are CXCL10 and CXCL9
expressed in RA and other arthritis related disease patients
[38–41], but they have been shown to be biomarkers for RA
symptoms, implying a similar mechanism for joint destruction in
CHIKV disease [42]. Moreover, CXCL9 and CXCL10 may be
contributors of persistent immune activation in CHIKV disease
leading to chronic symptoms, which implies cytokine immuno-
modulation may significantly improve patient treatment and
recovery. Importantly, CXCL10 also has prognostic value in the
treatment of viral hepatitis where CXCL10 levels follow disease
recovery [43] supporting our finding and proposes a prognostic
role for CXCL10 in CHIKV. Furthermore, our data puts forth
CXCL10 and CXCL9 as possible drug targets for treatment of
CHIKV symptoms in the convalescence phase due to the
association with severity; however, further investigation is needed
on CXCL10 and CXCL9 efficacy. In addition, not only are the
identified cytokines useful as possible drug targets but the cytokine
signatures described can also be applied when testing newly
developed CHIKV therapeutics. As CHIKV therapeutics are
evaluated in the CHIKV disease model, cytokine profiles can be
used as an output for determining the efficacy of the novel
therapeutics.
The synovial mast cell remains an important component during
RA joint destruction by the exocytosis of intracellular granules
containing inflammatory mediators. Currently, mast cell activation
through FccRs by high levels of circulating IgG antibodies is
hypothesized to contribute to the pathological destruction of
synovium in RA [44–46]. In addition, antibody immune complex
formation within the joint stabilizing inflammatory mediators,
such as chemokines and complement proteins, is another possible
low IgG level group (L) and a high IgG level group (H). Cytokine Bead Array analysis of the serum samples showed a significant difference in CXCL9,
CXCL10 and IL-6 between patients with high and low IgG levels at the 6-month time point. Twelve-month follow-up CHIKV patient samples showed a
significant difference in CXCL9 and IL-10 between low (1) and high (2) IgG groups. A Mann-Whitney U test was used to determine significance among
the IgG groups. The cross symbol indicates a p-value less than 0.05.
doi:10.1371/journal.pntd.0001279.g005
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www.plosntds.org 9 August 2011 | Volume 5 | Issue 8 | e1279Figure 6. CHIKV disease severity is associated with high CXCL10, CXCL9 and IgG levels at the 6-month time point. CHIKV patients
were determined to be nonsymptomatic (N), to have mild symptoms (M) or to have severe symptoms (S). The cytokine and IgG levels were then
grouped by symptom level and a Mann-Whitney U test was used to determine significance among the severity groups. CXCL10, CXCL9 and IgG were
found to be significantly increased in the patients with mild and severe symptoms at 6 months following initial infection. The cross symbol indicates a
p-value less than 0.05.
doi:10.1371/journal.pntd.0001279.g006
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concentrations of IgG to be associated with symptom severity in
CHIKV patients. Similar IgG mediated mechanisms leading to
synovium destruction and severe pain experienced by CHIKV
patients are possible. Taken together with the roles of IgG in RA,
our findings support the need for further investigation into the
contribution of IgG levels and mast cells to CHIKV symptoms.
We have found that the cytokines investigated had one of two
immunologically important profiles during CHIKV disease onset
and convalescence; furthermore, CXCL10 and CXCL9 were
makers of disease severity. By identifying the immune profiles, we
have created a clearer clinical picture of CHIKV disease.
Importantly, further investigation is needed to correlate these
profiles with disease onset and progression to use the cytokine
profiles as biomarkers for severity and symptom persistence. The
data presented here suggest that with further investigation,
immunomodulators may significantly enhance patient recovery.
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